Michael A Webster-Clark (Michael Webster-Clark)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 16

Top Topics

Ankylosing Spondylitis

Randomized Controlled Trial

Metastatic Colorectal Cancer

Top Venues

Pharmacoepidemiology and drug safety

American journal of epidemiology

Statistics in medicine

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jessica C Young, Michael A Webster-Clark, Shahar Shmuel, Elizabeth M Garry, Panagiotis Mavros, Til Stürmer, Cynthia J Girman
Clarifying the causal contrast: An empirical example applying the prevalent new user study design. Pharmacoepidemiology and drug safety 33 (4) (2024)
Michael A Webster-Clark, Kristian B Filion, Robert W Platt
Standardizing to specific target populations in distributed networks and multisite pharmacoepidemiologic studies. American journal of epidemiology 193 (7) (2024)
Michael A Webster-Clark, Rachael K Ross, Alexander P Keil, Robert W Platt
Variable selection when estimating effects in external target populations. American journal of epidemiology 193 (8) (2024)
Michael A Webster-Clark, Rachael K Ross, Alexander P Keil, Robert W Platt
Variable selection when estimating effects in external target populations. American journal of epidemiology 193 (8) (2024)
Michael A Webster-Clark, Kristian B Filion, Robert W Platt
Standardizing to specific target populations in distributed networks and multisite pharmacoepidemiologic studies. American journal of epidemiology 193 (7) (2024)
Michael A Webster-Clark, Rachael K Ross, Alexander P Keil, Robert W Platt
Variable selection when estimating effects in external target populations. American journal of epidemiology 193 (8) (2024)
Michael A Webster-Clark, Sengwee Toh, Jonathan Arnold, Kathleen M McTigue, Thomas Carton, Robert W Platt
External validity in distributed data networks. Pharmacoepidemiology and drug safety (2023)
Michael A Webster-Clark, Panagiotis Mavros, Elizabeth M Garry, Til Stürmer, Shahar Shmuel, Jessica C Young, Cynthia J Girman
Alternative analytic and matching approaches for the prevalent new-user design: A simulation study. Pharmacoepidemiology and drug safety 31 (7) (2022)
Emilie D Duchesneau, Bradford E Jackson, Michael A Webster-Clark, Jennifer L Lund, Katherine E Reeder-Hayes, Anna Maria Napoles, Paula D Strassle
The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 31 (11) (2022)
Di Shu, Michael A Webster-Clark, Robert W Platt, Sengwee Toh
Meta-analysis with sample-standardization in multi-site studies. Pharmacoepidemiology and drug safety (2022)
Michael A Webster-Clark, Alexander P Keil, Hanna K Sanoff, Til Stürmer, Daniel Westreich, Jennifer L Lund
Introducing longitudinal cumulative dose to describe chemotherapy patterns over time: Case study of a colon cancer trial. International journal of cancer 149 (2) (2021)
Michael A Webster-Clark, Ting-Ying Huang, Laura Hou, Sengwee Toh
Translating claims-based CHA2 DS2 -VaSc and HAS-BLED to ICD-10-CM: Impacts of mapping strategies. Pharmacoepidemiology and drug safety 29 (4) (2020)
Michael A Webster-Clark, Til Stürmer, Tiansheng Wang, Kenneth Man, Danica Marinac-Dabic, Kenneth J Rothman, Alan R Ellis, Mugdha Gokhale, Mark Lunt, Cynthia Girman, Robert J Glynn
Using propensity scores to estimate effects of treatment initiation decisions: State of the science. Statistics in medicine 40 (7) (2020)
Michael A Webster-Clark
Ways COVID-19 may impact unrelated pharmacoepidemiologic research using routinely collected data. Pharmacoepidemiology and drug safety 30 (3) (2020)
Michael A Webster-Clark, Til Stürmer, Jessie K Edwards, Charles Poole, Ross J Simpson, Jennifer L Lund
Real-world on-treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults. Pharmacoepidemiology and drug safety 29 (8) (2020)
Jennifer L Lund, Michael A Webster-Clark, Sharon Peacock Hinton, Shahar Shmuel, Til Stürmer, Hanna K Sanoff
Effectiveness of adjuvant FOLFOX vs 5FU/LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach. Pharmacoepidemiology and drug safety 29 (12) (2020)